CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Capital Com Australia Pty Ltd Australia (Regulated by ASIC) Capital Com UK Limited Authorised and regulated by the Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (Regulated by CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (Regulated by NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (Regulated by FSA) Capital Com Online Investments Ltd (Regulated by SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Also you can contact us: call +44 20 8089 7893 support@capital.com

Trade BioMarin Pharmaceutical Inc - BMRN CFD

110.26
0.74%
0.58
Low: 109.73
High: 111.54
Market Trading Hours* (UTC) Opens on Thursday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.58
Long position overnight fee

Long position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Biomarin Pharmaceutical Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 111.08
Open* 110.19
1-Year Change* 23.49%
Day's Range* 109.73 - 111.54
52 wk Range 70.73-117.77
Average Volume (10 days) 1.49M
Average Volume (3 months) 30.89M
Market Cap 20.69B
P/E Ratio 281.93
Shares Outstanding 185.85M
Revenue 2.01B
EPS 0.39
Dividend (Yield %) N/A
Beta 0.36
Next Earnings Date Feb 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 8, 2023 110.26 -0.18 -0.16% 110.44 111.55 109.28
Feb 7, 2023 111.08 0.35 0.32% 110.73 111.42 109.56
Feb 6, 2023 111.76 0.78 0.70% 110.98 112.83 109.93
Feb 3, 2023 111.72 -0.63 -0.56% 112.35 113.68 111.21
Feb 2, 2023 112.62 -3.05 -2.64% 115.67 116.34 111.50
Feb 1, 2023 116.50 2.14 1.87% 114.36 116.68 113.19
Jan 31, 2023 115.12 1.18 1.04% 113.94 115.38 113.94
Jan 30, 2023 114.47 -1.80 -1.55% 116.27 116.93 114.14
Jan 27, 2023 116.79 1.47 1.27% 115.32 117.56 115.32
Jan 26, 2023 116.58 1.07 0.93% 115.51 116.94 114.46
Jan 25, 2023 115.45 1.60 1.41% 113.85 116.29 113.84
Jan 24, 2023 113.39 3.30 3.00% 110.09 113.79 110.09
Jan 23, 2023 110.98 1.71 1.56% 109.27 111.38 108.74
Jan 20, 2023 110.47 1.35 1.24% 109.12 110.86 108.49
Jan 19, 2023 108.78 -1.10 -1.00% 109.88 109.96 108.60
Jan 18, 2023 110.28 -0.81 -0.73% 111.09 111.73 110.15
Jan 17, 2023 111.36 0.36 0.32% 111.00 112.79 109.88
Jan 13, 2023 112.27 1.12 1.01% 111.15 114.58 110.75
Jan 12, 2023 112.91 2.89 2.63% 110.02 113.43 108.97
Jan 11, 2023 110.68 -0.47 -0.42% 111.15 112.46 108.79

BioMarin Pharmaceutical Inc Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 1116.85 1313.65 1491.21 1704.05 1860.45 1846.28
Revenue 1116.85 1313.65 1491.21 1704.05 1860.45 1846.28
Cost of Revenue, Total 209.62 241.786 315.264 359.466 524.272 470.515
Gross Profit 907.234 1071.86 1175.95 1344.58 1336.18 1375.76
Total Operating Expense 1920.28 1328.35 1614.74 1804.51 1897.22 1928.62
Selling/General/Admin. Expenses, Total 472.976 565.167 610.014 675.665 737.784 760.923
Research & Development 661.905 610.753 696.328 715.007 628.116 628.793
Depreciation / Amortization 30.2 36.2 30.3 53.5 62.2 61.9
Interest Expense (Income) - Net Operating 3.617 -10.831 -5.661 5.259 -0.115 -1.548
Unusual Expense (Income) 599.118 -125 -50 -25 -59.495 0
Other Operating Expenses, Total -57.153 10.271 18.491 20.608 4.458 8.033
Operating Income -803.429 -14.7 -123.524 -100.457 -36.765 -82.341
Interest Income (Expense), Net Non-Operating -32.55 -29.145 -21.386 -1.299 -12.705 -4.855
Other, Net 4.929 7.97 2.205 6.945 7.148 11.846
Net Income Before Taxes -831.05 -35.875 -142.705 -94.811 -42.322 -75.35
Net Income After Taxes -630.21 -74.742 -77.211 -23.848 4.561 -68
Net Income Before Extra. Items -630.21 -74.742 -77.211 -23.848 4.561 -68
Net Income -630.21 -117.042 -77.211 -23.848 859.1 -64.08
Income Available to Common Excl. Extra. Items -630.21 -74.742 -77.211 -23.848 4.561 -68
Income Available to Common Incl. Extra. Items -630.21 -117.042 -77.211 -23.848 859.1 -64.08
Diluted Net Income -630.21 -117.042 -77.211 -23.848 859.1 -64.08
Diluted Weighted Average Shares 165.985 174.427 177.061 179.039 191.678 182.852
Diluted EPS Excluding Extraordinary Items -3.79679 -0.4285 -0.43607 -0.1332 0.0238 -0.37189
Diluted Normalized EPS -1.45063 -0.89431 -0.61962 -0.22396 -0.17796 -0.37189
Total Extraordinary Items -42.3 0 854.539 3.92
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 486.03 501.693 408.742 449.81 519.359
Revenue 486.03 501.693 408.742 449.81 519.359
Cost of Revenue, Total 120.166 127.062 103.537 119.75 116.965
Gross Profit 365.864 374.631 305.205 330.06 402.394
Total Operating Expense 460.944 490.021 461.961 515.69 382.032
Selling/General/Admin. Expenses, Total 174.318 184.161 183.333 217.563 194.619
Research & Development 148.725 161.107 157.869 161.092 160.836
Depreciation / Amortization 15.4 15.5 15.4 15.6 15.6
Unusual Expense (Income) 0 0 0 0 -108
Other Operating Expenses, Total 2.335 2.191 1.822 1.685 2.012
Operating Income 25.086 11.672 -53.219 -65.88 137.327
Interest Income (Expense), Net Non-Operating -2.716 0.479 -1.866 -0.752 -1.986
Other, Net 0.858 2.005 8.925 0.058 -1.154
Net Income Before Taxes 23.228 14.156 -46.16 -66.574 134.187
Net Income After Taxes 17.371 12.941 -36.494 -61.818 120.798
Net Income Before Extra. Items 17.371 12.941 -36.494 -61.818 120.798
Net Income 17.371 12.941 -36.494 -57.898 120.798
Income Available to Common Excl. Extra. Items 17.371 12.941 -36.494 -61.818 120.798
Income Available to Common Incl. Extra. Items 17.371 12.941 -36.494 -57.898 120.798
Diluted Net Income 17.371 12.941 -36.494 -57.898 120.798
Diluted Weighted Average Shares 184.365 185.427 183.214 183.56 194.886
Diluted EPS Excluding Extraordinary Items 0.09422 0.06979 -0.19919 -0.33677 0.61984
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.09422 0.06979 -0.19919 -0.33677 0.12096
Total Extraordinary Items 3.92
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 1421.79 2207.14 2056.22 1942.14 2342.22 2274.39
Cash and Short Term Investments 789.677 1395.97 1084.31 753.807 1065.39 1013.88
Cash & Equivalents 408.33 598.028 493.982 437.446 649.158 587.276
Short Term Investments 381.347 797.94 590.326 316.361 416.228 426.599
Total Receivables, Net 215.28 261.365 342.633 377.404 448.351 373.399
Accounts Receivable - Trade, Net 215.28 261.365 342.633 377.404 448.351 373.399
Total Inventory 355.126 475.775 530.871 680.275 698.548 776.669
Other Current Assets, Total 61.708 74.036 98.403 130.657 129.934 110.442
Total Assets 4023.69 4633.12 4427.13 4690.04 5848.02 6003.33
Property/Plant/Equipment, Total - Net 798.768 896.7 948.682 1070.3 1089.58 1081.88
Property/Plant/Equipment, Total - Gross 1141.36 1303.43 1421.32 1619.4 1725.18 1802.45
Accumulated Depreciation, Total -342.594 -406.734 -472.635 -549.1 -635.595 -720.574
Goodwill, Net 197.039 197.039 197.039 197.039 196.199 196.199
Intangibles, Net 553.78 517.51 491.808 456.58 417.271 388.652
Long Term Investments 572.711 385.785 235.864 411.978 285.473 507.793
Other Long Term Assets, Total 479.601 428.947 497.52 611.997 1517.28 1554.42
Total Current Liabilities 439.31 816.518 523.241 932.503 492.548 539.822
Payable/Accrued 198.53 161.652 208.119 240.981 191.429 193.003
Accrued Expenses 158.926 201.601 213.03 287.878 266.254 277.059
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 22.478 360.949 0 365.131 2.865 2.266
Other Current Liabilities, Total 59.376 92.316 102.092 38.513 32 67.494
Total Liabilities 1257.42 1824.46 1459.19 1567.66 1742.02 1732.58
Total Long Term Debt 660.761 813.521 830.417 492.946 1079.15 1081.04
Long Term Debt 660.761 813.521 830.417 486.238 1075.15 1079.08
Deferred Income Tax 0
Other Liabilities, Total 157.344 194.423 105.53 142.209 170.319 111.726
Total Equity 2766.27 2808.66 2967.94 3122.38 4106 4270.74
Common Stock 0.173 0.176 0.178 0.18 0.182 0.184
Additional Paid-In Capital 4288.11 4483.22 4669.93 4832.71 4993.41 5191.5
Retained Earnings (Accumulated Deficit) -1520.51 -1637.55 -1694.13 -1720.71 -861.609 -925.689
Other Equity, Total -1.505 -34.463 -6.113 6.638 -29.867 6.116
Total Liabilities & Shareholders’ Equity 4023.69 4633.12 4427.13 4690.04 5848.02 6003.33
Total Common Shares Outstanding 172.648 175.844 178.253 179.838 181.741 183.913
Unrealized Gain (Loss) -2.722 -1.917 3.565 3.889 -1.373
Capital Lease Obligations 6.708 4.006 1.96
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 2288.77 2357.84 2311.57 2274.39 2394.02
Cash and Short Term Investments 1087.49 1123.4 1079.48 1013.88 1056.24
Cash & Equivalents 667.313 641.533 617.143 587.276 605.44
Short Term Investments 420.178 481.864 462.333 426.599 450.798
Total Receivables, Net 396.097 424.419 374.937 373.399 430.147
Accounts Receivable - Trade, Net 396.097 424.419 374.937 373.399 430.147
Total Inventory 713.929 710.975 749.406 776.669 786.356
Other Current Assets, Total 91.249 99.046 107.751 110.442 121.283
Total Assets 5805.05 5898.5 5977.48 6003.33 6062.71
Property/Plant/Equipment, Total - Net 1022.47 1026.58 1024.79 1035.46 1039.54
Property/Plant/Equipment, Total - Gross 1679.77 1704.7 1724.7 1756.04 1780.71
Accumulated Depreciation, Total -657.296 -678.126 -699.915 -720.574 -741.167
Goodwill, Net 196.199 196.199 196.199 196.199 196.199
Intangibles, Net 405.903 394.298 388.487 388.652 374.251
Long Term Investments 321.127 350.237 466.618 507.793 462.827
Other Long Term Assets, Total 1570.58 1573.35 1589.81 1600.83 1595.86
Total Current Liabilities 430.035 443.344 514.898 539.822 490.418
Payable/Accrued 165.001 176.073 203.321 203.467 187.81
Accrued Expenses 209.203 207.005 241.535 268.861 214.435
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 55.831 60.266 70.042 67.494 88.173
Total Liabilities 1643.04 1656.93 1711.33 1732.58 1671.39
Total Long Term Debt 1076.13 1077.11 1078.09 1079.08 1080.06
Long Term Debt 1076.13 1077.11 1078.09 1079.08 1080.06
Other Liabilities, Total 136.881 136.471 118.335 113.686 100.913
Total Equity 4162.01 4241.57 4266.15 4270.74 4391.31
Common Stock 0.183 0.183 0.184 0.184 0.185
Additional Paid-In Capital 5010.62 5083.83 5133.74 5191.5 5206.29
Retained Earnings (Accumulated Deficit) -844.238 -831.297 -867.791 -925.689 -804.891
Unrealized Gain (Loss) 2.387 1.821 1.218 -1.373 -9.264
Other Equity, Total -6.941 -12.967 -1.204 6.116 -1.002
Total Liabilities & Shareholders’ Equity 5805.05 5898.5 5977.48 6003.33 6062.71
Total Common Shares Outstanding 182.671 183.322 183.567 183.913 184.902
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -630.21 -117.042 -77.211 -23.848 859.1 -64.08
Cash From Operating Activities -227.837 -8.757 20.208 48.262 85.365 304.536
Cash From Operating Activities 96.912 87.861 95.671 105.3 105.172 108.039
Deferred Taxes -228.054 44.464 -68.378 -82.76 -888.907 -15.608
Non-Cash Items 693.791 69.923 119.546 150.662 234.417 210.151
Cash Taxes Paid 95.857 23.895 16.676 9.726 8.977 18.153
Cash Interest Paid 8.643 8.544 11.623 8.552 12.178 10.395
Changes in Working Capital -160.276 -93.963 -49.42 -101.092 -224.417 66.034
Cash From Investing Activities -484.047 -305.459 264.351 -31.026 -53.621 -366.313
Capital Expenditures -148.38 -199.219 -144.62 -163.406 -137.519 -119.225
Other Investing Cash Flow Items, Total -335.667 -106.24 408.971 132.38 83.898 -247.088
Cash From Financing Activities 727.108 507.145 -388.007 -74.674 181.118 -0.048
Financing Cash Flow Items -60.057 -35.427 -80.542 -101.198 -44.638 -46.203
Issuance (Retirement) of Stock, Net 787.165 60.859 67.488 31.611 21.913 49.194
Foreign Exchange Effects -3.934 -3.231 -0.598 0.902 -1.15 -0.057
Net Change in Cash 11.29 189.698 -104.046 -56.536 211.712 -61.882
Issuance (Retirement) of Debt, Net 481.713 -374.953 -5.087 203.843 -3.039
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 17.371 30.312 -6.182 -64.08 120.798
Cash From Operating Activities 113.512 196.296 293.356 304.536 -45.431
Cash From Operating Activities 27.983 55.214 82.053 108.039 27.343
Deferred Taxes 3.335 1.204 -12.02 -15.608 4.8
Non-Cash Items 56.553 111.414 163.355 210.151 -61.68
Cash Taxes Paid 2.998 10.159 15.531 18.153 1.316
Cash Interest Paid 1.465 5.195 6.673 10.395 1.422
Changes in Working Capital 8.27 -1.848 66.15 66.034 -136.692
Cash From Investing Activities -70.788 -191.045 -310.892 -366.313 87.782
Capital Expenditures -28.254 -54.506 -74.866 -119.225 -30.675
Other Investing Cash Flow Items, Total -42.534 -136.539 -236.026 -247.088 118.457
Cash From Financing Activities -24.364 -13.413 -14.444 -0.048 -25.28
Financing Cash Flow Items -29.097 -39.112 -44.829 -46.203 -32.949
Issuance (Retirement) of Stock, Net 5.817 27.64 32.877 49.194 8.235
Issuance (Retirement) of Debt, Net -1.084 -1.941 -2.492 -3.039 -0.566
Foreign Exchange Effects -0.205 0.537 -0.035 -0.057 1.093
Net Change in Cash 18.155 -7.625 -32.015 -61.882 18.164
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
PRIMECAP Management Company Investment Advisor 9.4838 17625505 -52980 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.1613 17026106 263453 2022-09-30 LOW
Dodge & Cox Investment Advisor/Hedge Fund 7.9494 14773963 -233100 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.3137 9875458 113895 2022-09-30 LOW
Baker Bros. Advisors LP Hedge Fund 4.1004 7620494 0 2022-09-30 LOW
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 3.0607 5688259 129970 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.8402 5278438 -117928 2022-09-30 LOW
Viking Global Investors LP Investment Advisor/Hedge Fund 2.7437 5099164 46571 2022-09-30
Capital Research Global Investors Investment Advisor 2.6563 4936740 1394 2022-09-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 2.2221 4129724 -71509 2022-09-30 LOW
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 1.9131 3555555 271555 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.353 2514523 42707 2022-09-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.2642 2349540 223693 2021-12-31 LOW
Parnassus Investments, LLC Investment Advisor 1.2583 2338529 -227551 2022-12-31 LOW
Barclays Bank PLC Investment Advisor 1.1309 2101767 182659 2022-09-30 MED
Palo Alto Investors LP Hedge Fund 1.0634 1976265 -85108 2022-09-30 LOW
Millennium Management LLC Hedge Fund 1.0085 1874272 348269 2022-09-30 HIGH
Amundi Asset Management, SAS Investment Advisor/Hedge Fund 0.9306 1729432 1607478 2022-09-30 HIGH
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 0.924 1717310 17600 2022-09-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.7732 1437057 -102057 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+500000+

Traders

93000+

Active clients monthly

$57000000+

Monthly investing volume

$31000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Past performance is not a reliable indicator of future results
Profit/Loss

BioMarin Company profile

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioMarin Pharmaceutical Inc. revenues decreased 1% to $1.85B. Net loss before extraordinary items totaled $68M vs. income of $4.6M. Revenues reflect Kuvan1 segment decrease of 38% to $285.8M, Naglazyme1 segment decrease of 3% to $380.4M, United States segment decrease of 28% to $657.7M, Latin America segment decrease of 7% to $191.2M.

Equity composition

Common Stock $.001 Par, 04/11, 250M auth., 110,909,591 issd. Insiders own 0.26%. IPO 7/23/99, 4.5M shs. $13 by U.S. Bancorp Piper Jaffray. PO 12/01, 8,050,000 shs. @ $12 by UBS Warburg. 5/01, private placement 4,763,712 shares @ $9.45. PO 2/03, 7.5M shs @ $10 by UBS Warburg. PO 3/06 10,350,000 shs. @ $13/sh.

Industry: Biopharmaceuticals

105 Digital Dr
NOVATO
CALIFORNIA 94949
US

Income Statement

  • Annual
  • Quarterly

News

Stock market indicators and cash dollars

Markets look for guidance after Powell speech, eyeing US CPI: USD, S&P 500, DAX 40

Us equities try to build appetite to push higher after Powell acknowledges disinflation during his speech

12:34, 8 February 2023
The XRP coin on a gavel

Ripple/SEC Lawsuit: News And Update

Ripple and the US Securities and Exchange Commission are still awaiting a ruling

15:00, 7 February 2023
Gold outlook

Gold Price Forecast: Gold Loses Shine as USD and US Yields Edge Higher

Gold correcting lower on USD comeback. Eyes on Chair Powell to exacerbate Gold downside

12:41, 7 February 2023
Close-Up Of Paper Currency

Australian Dollar Outlook: AUD/USD bounces back as RBA hikes 25bps

AUS/USD bounces higher as RBA delivers its 9th rate hike

11:28, 7 February 2023
Japanese Yen Outlook

Japanese Yen Outlook: USD/JPY Edging Towards YTD Peak on BoJ Dove and US Yields

Japanese Yen underperforms with BoJ dove touted to be Governor Kuroda successor.

14:36, 6 February 2023

People also watch

XRP/USD

0.40 Price
-1.330% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00412

Natural Gas

2.47 Price
-6.170% 1D Chg, %
Long position overnight fee -0.1217%
Short position overnight fee 0.0860%
Overnight fee time 22:00 (UTC)
Spread 0.005

Oil - Crude

78.63 Price
+1.160% 1D Chg, %
Long position overnight fee -0.0163%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 0.03

US100

12,542.20 Price
-1.230% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0077%
Overnight fee time 22:00 (UTC)
Spread 1.8

Market analysis

Two €50 banknotes on a map of Europe

Euro forecast: Will EUR continue rising?

18:38, 8 February 2023
Close-up of a $20 banknote and gold bullion

Gold price forecast for 2023 and beyond: Will the dollar keep it down?

17:21, 8 February 2023
Signage outside the entrance of the Reserve Bank of Australia building in Sydney, Australia.

Projected Australia interest rate in 5 years: RBA determined to dampen persistent inflation

16:44, 8 February 2023

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading